Educating Patients on Complications Associated with CAR T-Cell Therapy
The panel provides clinical insights on talking with patients about complications associated with CAR T-cell therapy.
EP: 1.Identifying Potential Candidates for CAR T-Cell Therapy
EP: 2.Treating Patients Referred to Academic Centers for CAR T
EP: 3.CAR T-Cell Therapy: Leukapheresis Practices
EP: 4.Triaging and Prioritizing Patients with Multiple Myeloma
EP: 5.Transitioning Patients Back to Community Practices Following CAR T
EP: 6.Monitoring Adverse Events Following CAR T-Cell Therapy
EP: 7.Educating Patients on Complications Associated with CAR T-Cell Therapy
EP: 8.Improving Access for Patients Receiving CAR T-Cell Therapy
EP: 9.Collaborative Education for CAR T-Cell Therapy
EP: 10.Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings
- Dr Park: What protocols and processes do you have in place at the community practice to continue monitoring and managing potential long-term complications or adverse events associated with CAR T-cell therapy?
- How do you approach monitoring for and managing late-onset neurotoxicity or other long-term adverse effects that may occur after the patient transitions back to the community setting?
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
